- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:48 | Propanc Biopharma, Inc.: Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models | 53 | GlobeNewswire (Europe) | MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| Do | Propanc Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.02. | Propanc Biopharma, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 18.02. | Propanc Biopharma, Inc. GAAP EPS of -$0.30 | 1 | Seeking Alpha | ||
| 18.02. | Propanc Biopharma files four new patent applications for cancer treatment | 1 | Investing.com | ||
| 18.02. | Propanc Biopharma, Inc.: Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results | 199 | GlobeNewswire (Europe) | MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for recurrent and... ► Artikel lesen | |
| PROPANC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 17.02. | Propanc Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.02. | Propanc Biopharma, Inc.: Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market | 2 | GlobeNewswire (USA) | ||
| 02.02. | Propanc Biopharma, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 27.01. | Propanc Biopharma, Inc.: Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations | 5 | GlobeNewswire (USA) | ||
| 20.01. | Propanc Biopharma files new patent for synthetic cancer treatment | 2 | Investing.com | ||
| 20.01. | Propanc Biopharma meldet neues Patent für synthetische Krebstherapie an | - | Investing.com Deutsch | ||
| 20.01. | Propanc Biopharma, Inc.: Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia | 141 | GlobeNewswire (Europe) | MELBOURNE,, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases... ► Artikel lesen | |
| 15.01. | Propanc Biopharma advances pancreatic cancer treatment toward clinical trials | 2 | Investing.com | ||
| 15.01. | Propanc Biopharma, Inc.: Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 13.01. | Propanc Biopharma, Inc.: Propanc Biopharma Provides Shareholder Update | 165 | GlobeNewswire (Europe) | MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 07.01. | Propanc Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.12.25 | Propanc Biopharma, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 22.12.25 | Propanc Biopharma, Inc.: Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal | 2 | GlobeNewswire (USA) | ||
| 04.12.25 | Propanc Biopharma, Inc.: Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs | 213 | GlobeNewswire (Europe) | MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for chronic diseases... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,304 | -6,72 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| QIAGEN | 40,700 | -1,44 % | Shortseller-Positionen aktuell: freenet, GFT, HelloFresh, Hypoport, Puma, Qiagen, Redcare Pharmacy | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AMGEN | 324,05 | -1,77 % | Amgen EVP Sold $20.77M In Company Stock | ||
| BIOFRONTERA | 2,790 | +4,10 % | Paradigmenwechsel in der onkologischen Dermatologie: Vidac Pharma als Innovator, was machen Almirall und Biofrontera? | Die onkologische Dermatologie steht an der Schwelle zu einer Revolution, die das bisherige Verständnis der Krebsbehandlung grundlegend verändern könnte. Der globale Markt für die Behandlung der Aktinischen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 50,50 | -2,88 % | Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? | ||
| BIONXT SOLUTIONS | 0,389 | -0,26 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement | VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated... ► Artikel lesen | |
| NOVONESIS | 49,690 | -0,54 % | Novozymes Reports Climb In Q4 Bottom Line | BRUSSELS (dpa-AFX) - Novozymes (NVZMF.PK) reported earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings came in at EUR122.8 million, or EUR1.25... ► Artikel lesen | |
| TEMPUS AI | 45,200 | -0,88 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| GENMAB | 236,80 | -6,62 % | Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise | The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as of 27 February 2026 in the ISIN below.
ISIN:
DK0010272202
Name:
Genmab
Volume... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| EXACT SCIENCES | 89,07 | +0,76 % | Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval | ||
| IMMUNITYBIO | 8,838 | -0,90 % | ImmunityBio Q4 2026 Earnings Preview | ||
| TME PHARMA | 0,061 | -11,16 % | TME Pharma NV: TME Pharma provides update on its activities | TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| CYTODYN | 0,195 | 0,00 % | CytoDyn Inc.: December 2025 Letter to Shareholders | VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,465 | -4,55 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen |
PROPANC BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,183 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROPANC BIOPHARMA INC finden Sie auf Wallstreet Online.